Select region:

Clinical trials located in

Warsaw

Warsaw city is located in Poland. Currently, 20 clinical trials are being conducted in this city.

Warsaw, Poland’s vibrant capital, stands as a testament to resilience and rebirth. Founded around the 13th century, it has been the nation’s political and cultural hub for centuries. The city’s landscape is a mosaic of historical architecture and modern skyscrapers, symbolizing its recovery from near-total destruction during World War II. Warsaw is home to the largest university in Poland, the University of Warsaw, and the iconic Warsaw Uprising Museum, which commemorates the city’s heroic 1944 uprising against Nazi occupation. The city also boasts the lush Lazienki Park, featuring palaces, an amphitheater, and peacocks, highlighting Warsaw’s blend of natural beauty and historical significance.

  • CT-EU-00111902

    Sparsentan Treatment Study for Children with Kidney Diseases

    We are excited to introduce a clinical trial focused on the study of Sparsentan treatment in children and adolescents with certain types of kidney diseases that lead to protein loss in urine, known as proteinuric glomerular diseases. This includes conditions like Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), IgA Vasculitis (IgAV), and Alport Syndrome (AS).

    The main goal of this study is to understand how safe, effective, and tolerable Sparsentan is when given as an oral suspension or tablet. We are particularly interested in seeing how this treatment can change the levels of protein in the urine over a period of 108 weeks.

    This study is designed as a Phase 2, Open-Label, Single-Arm trial, meaning all participants will receive the treatment, and there will not be a comparison group receiving a placebo. We are looking to enroll approximately 67 pediatric subjects, aged 1 year to less than 18 years, who have been diagnosed with one of the specified conditions. The study is divided into three populations based on the specific disease and age groups, with different dosages of Sparsentan being tested across these groups.

    The safety of the participants will be closely monitored throughout the study, with a special focus on any treatment-emergent adverse events, serious adverse events, and any adverse events that may lead to discontinuation of the treatment. Additionally, we will measure the change in the urine protein/creatinine ratio (UP/C) from the start of the study to week 108 to assess the effectiveness of Sparsentan in reducing proteinuria.

    This study represents an important step towards finding a potentially effective treatment for children and adolescents suffering from these challenging kidney diseases. If you or your child are dealing with one of these conditions and are interested in participating, we encourage you to consider this unique opportunity.

    GermanyItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • The safety of naxitamab treatment combined with standard chemotherapy in patients with Ewing’s sarcoma resistant to conventional therapy

    This study is focused on exploring a new approach to help individuals with a tough-to-treat cancer called Ewing’s Sarcoma, particularly for those between the ages of 2 to 21. The treatment being tested is called naxitamab in combination with a standard chemotherapy regimen. The main goal is to understand how safe this treatment is and how well it might work for those whose cancer has not responded well to standard treatments.

    The therapy under investigation involves a unique method targeting a specific component found on the surface of some cancer cells, known as GD2. The study will combine naxitamab, which is designed to recognize and attach to GD2, with chemotherapy drugs irinotecan and temozolomide, which are already used to treat this type of cancer. This combination aims to enhance the effectiveness of the treatment.

  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    AustriaFranceGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    AustriaBelgiumFranceGermanyItalyNetherlandsNorwayPolandPortugalSlovakiaSpainUnited Kingdom
  • CT-EU-00057401

    Testing new pressure microcatheter vs traditional pressure wire in heart diseases

    The clinical trial is a research study about two devices that doctors use to measure the severity of a person’s heart problem: a pressure microcatheter and a pressure wire. The new device, a pressure microcatheter, is easier to use and simplifiles pullback maneuvers compared to the pressure wire. The study is done with patients with stable coronary artery disease or stabilised non-ST elevation acute coronary syndrome (ACS) with epicardial stenosis considered for PCI. The goal is to see if using the pressure microcatheter is as good as using the pressure wire. Doctors will use these devices to guide the treatment and improve the heart’s blood flow. The patient will be monitored in the hospital for a year and then checked yearly for five years. The researchers will be evaluating several things including the patient’s health outcomes, the cost and time of the procedure, and the effectiveness of the devices.

    BelgiumGermanyPolandSpain
  • Study on the benefits of combined therapy for high-risk non-muscle invasive bladder cancer

    This research study is focused on investigating the safety and effectiveness of a medication called Pembrolizumab (MK-3475) when combined with Bacillus Calmette-Guerin (BCG) treatment in individuals with high-risk bladder cancer that has not spread to the muscle. The study involves two groups of patients: those who have not responded well to BCG alone and those who have not received BCG previously. For the first group, the primary objective is to determine if the combination of Pembrolizumab and BCG is more effective than BCG alone in eliminating their cancer. For the second group, the goal is to assess whether the combination therapy improves the likelihood of survival without any cancer-related events compared to BCG alone.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Testing Nipocalimab’s effect on adults with Muscle Weakness

    This study is about a new drug called nipocalimab for patients with a disease called Myasthenia Gravis (MG). MG patients feel weak in their muscles, and nipocalimab potentially could help to lessen this weakness. The drug functions by attaching itself to certain components of the blood to lessen the reaction causing muscle weakness. This large-scale study will take place in multiple hospitals and is organized in different phases including initial checks (4 weeks), treatment (24 weeks) and follow-ups (up to 2 years). It will be measured how well the treatment works through daily activity scores and strength tests.

    BelgiumCzechiaDenmarkFranceGermanyItalyPolandSpainSweden
  • Testing the effect of the new drug on Crohn’s Disease

    This study is exploring a new medication for Crohn’s disease, an ailment of the gut. The medication, known as BI 706321, is given alongside another medication called Ustekinumab that is already used to treat Crohn’s. The trial is conducted to see if this combination helps to manage the disease better. Participants will be split into two groups. One group will be given the new medication and the other will receive a placebo, alongside Ustekinumab. Participating in this study will last for 1 year. During this time, participants will have about 13 visits to the clinic. Some visits will involve a colonoscopy where doctors look at the intestine’s condition. Their findings will help doctors understand if the new treatment is working.

    BelgiumCzechiaDenmarkGermanyHungaryItalyNetherlandsPolandSpain
  • Studying the safety and effectiveness of a new drug for ulcerative colitis

    This study focuses on examining a drug called ABBV-668, administered in oral capsules, to evaluate its safety and effectiveness in the treatment of adults with ulcerative colitis, a gastrointestinal disease characterized by bleeding and inflammation in the large intestine. About 40 participants will take the capsules twice a day for 16 weeks. After this treatment period, doctors will continue to monitor participants for an additional month. The study involves visiting a doctor more often than usual, carefully checking for potential side effects, and asking participants-specific questions. To measure changes in participants’ condition, doctors will use a special scoring system.

    BelgiumFrancePoland
  • Testing brepocitinib medicine’s effect on adult skin and muscle disease

    This study is going to check if a medicine called brepocitinib can help adults with a skin and muscle disease called dermatomyositis. The researchers are making sure that patient results are accurate by giving some people the actual medicine and others a placebo, which has no active substance. The researchers are comparing two different amounts of the medicine against the placebo one to see if the patients get better. It will be tracked by creating a score based on how severe 6 different signs of the disease are, and then tallying up these scores over a period of one year. Those who are part of this one year study can choose to extend their participation for another year, where everyone gets the medicine with active substance. The researchers determine if the patient has improved by looking for an increase in their score of 40 points or more. And also look at how well a person can do their daily tasks, and also score the severity of any skin issues they have at the start and end of the study to check for changes.

    BelgiumBulgariaCzechiaGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    AustriaFranceGermanyNetherlandsPolandUnited Kingdom
  • Study on the effectiveness of Ozanimod in treating Ulcerative Colitis

    This study is focused on evaluating the effectiveness and safety of ozanimod, a medication, in children with active ulcerative colitis, a challenging gastrointestinal condition associated with intense pain. The primary objective of the study is to investigate whether ozanimod, administered orally, can provide relief from the symptoms of active ulcerative colitis in children. Additionally, the study aims to assess the safety profile of ozanimod in this pediatric population.

    BelgiumFranceGermanyPolandSpainUnited Kingdom
  • Testing ravulizumab for transplant-related blood complications

    The study is examining a drug called ravulizumab used in adults and teenagers with a blood vessel disease called thrombotic microangiopathy (TMA) after a bone marrow transplant. Sometimes, new cells growing after a bone marrow transplant can cause problems in the blood vessels leading to TMA. So this study will investigate whether ravulizumab can help in this situation. In the first stage, each participant will receive the drug to determine the best dose. In the second phase, some will receive ravulizumab and best supportive care, while others will receive placebo and best supportive care. After 26 weeks of treatment, doctors will continue to monitor and record the patients’ health for another 26 weeks. Special blood tests will be done to check if the medicine is working.

    BelgiumFranceGermanyGreeceItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Exploring magrolimab use for head and neck tumors

    This is a study about treatment of patients with squamous cell carcinoma, a type of head and neck cancer. The study will test the safety and effectiveness of a drug called magrolimab, used together with other cancer treatments. The study wants to know how well the treatment works. Throughout the trial, participants’ health will be closely monitored. This includes regular medical check-ups, imaging tests, and other diagnostic procedures to assess how well the cancer is responding to the treatment regimen.

    BelgiumFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Study on combination therapies for Metastatic Castration-Resistant Prostate Cancer

    The clinical trial is being conducted for advanced prostate cancer, specifically metastatic castration-resistant prostate cancer. In this study, a novel drug, Pembrolizumab, is being tested in combination with other treatments. There are ten groups in the trial, each receiving a different combination of treatments, all incorporating Pembrolizumab. The primary objectives include assessing the effectiveness and safety of these treatment combinations for patients with advanced prostate cancer. Patient group allocation is based on their previous treatments, and participants may have the opportunity to restart treatments if they discontinue for reasons other than disease progression.

    AustriaDenmarkFinlandFranceGermanyItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Long-term study on the effectiveness of mirikizumab for Crohn’s Disease

    This research study is about a long-term test of a medicine called Mirikizumab for people who have Crohn’s disease. The main aim of this study is to know if the medicine is effective and safe for those people eventually. The effect of the medicine will be checked using different tests and scores like the Simple Endoscopic Score for Crohn’s Disease, the Crohn’s Disease Activity Index, and patient-reported outcomes. Researchers will also be checking changes in certain markers in the blood and stool that can show inflammation.

    BelgiumCzechiaGermanyHungaryItalyPolandRomaniaSlovakiaSpainUnited Kingdom
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Investigating the use of a new treatment for motor neuropathy in adults

    This is a study to investigate the safety and effectiveness of a drug known as Empasiprubart (ARGX-117) in adults diagnosed with multifocal motor neuropathy. The goal is to understand how the drug behaves in the body over long periods of time and assess potential immune responses. During the study, participants’ arm and leg muscle strength will be assessed using a scoring system, with higher scores indicating better muscle strength. Grip strength will be measured by exerting force on the device. The purpose of these assessments is to gain insight into muscle functionality. Additionally, participants will undertake various tasks and communicate their feelings and experiences related to their health and everyday activities. This information will contribute to understanding the effectiveness of the drug and its impact on improving participants’ condition.

    AustriaBelgiumFranceGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainUnited Kingdom

See more clinical trials in other cities in Poland:

.